Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG2918
- Development stage
- Phase 2
- Lead developer
- Shangjian Bio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SG2918 is an antibody-drug conjugate (ADC) developed for the treatment of advanced malignant tumors. It consists of a monoclonal antibody targeting leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker. Upon binding to LILRB4 on tumor cells, the ADC is internalized, and MMAE is released intracellularly. MMAE then binds to tubulin and inhibits its polymerization, resulting in G2/M phase cell cycle arrest and apoptosis of cancer cells[1][6]. Preclinical studies indicate that SG2918 has significant anti-tumor activity both as monotherapy and in combination with anti-PD-1 antibodies[6]. The drug is currently being evaluated in Phase I clinical trials for patients with advanced solid tumors who are refractory or resistant to standard therapies[2][5][7].
- Other names
- anti-LILRB4/MMAE ADC SG2918
02
Targets
LILRB4
Beyond the preview
Go deeper on SG2918.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG2918.